FDA’s 12-Digit NDC Rule Will Reshape Drug Labeling

The FDA has finalized a new format for the National Drug Code, the number used to identify drug products sold in the United States. Beginning March 7, 2033, all FDA-assigned NDCs will use 12 digits arranged in a uniform 6-4-2 format: six digits for the labeler, four for the product and two for the package. Existing NDCs will be converted by adding leading zeros to the appropriate sections.

Current NDCs contain 10 digits, but they can be arranged in several formats. Depending on the product, the number may follow a 4-4-2, 5-3-2 or 5-4-1 structure. Other parts of the healthcare system often convert those numbers into an 11-digit format for billing and reimbursement. Every conversion creates another place where a digit can be added to the wrong section or associated with the wrong product.

FDA selected the 12-digit format partly because it is running out of available five-digit labeler codes. Continuing under the current structure would eventually add two more NDC formats, increasing the number of configurations used across healthcare. A single 6-4-2 structure gives manufacturers, pharmacies, distributors and healthcare systems one consistent way to store and exchange the number.

The rule also changes what can appear in a drug barcode. FDA will allow either linear or nonlinear formats when they follow a recognized industry standard. Under GS1 standards, a Data Matrix barcode can encode the new 12-digit NDC using application identifier 715. The same code can also contain the product’s serial number, lot number and expiration date. Beginning in 2033, one Data Matrix may satisfy both the FDA barcode requirement and the Drug Supply Chain Security Act product identifier requirement for qualifying products.

The transition will take time. FDA will continue assigning 10-digit NDCs until the rule takes effect. A three-year labeling transition will then run from March 7, 2033, through March 6, 2036, allowing companies to update labels and use existing inventory. During that period, software and inspection systems may encounter both 10-digit and 12-digit NDCs. Drugs labeled with the old format after the transition may face regulatory action.

For pharmaceutical manufacturers and their print partners, preparation goes well beyond changing the length of a number. Label templates, databases, barcode-generation software and inspection rules will need to recognize the new structure. Data Matrix codes must still meet size, contrast and readability requirements on cartons, bottles and other packaging. When serialization is involved, the system must confirm that the printed NDC, serial number, lot and expiration date match the production record.

The 2033 effective date provides a long runway, but pharmaceutical labeling changes move slowly. Equipment, software and production processes often require validation before they can be used. Starting early gives companies time to test both formats, update data connections and establish inspection procedures without forcing every change through at the end of the transition.